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Abstract
Background: There is a rise in incidence of esophageal carcinoma due to increasing incidence of adenocarcinoma.
Probably the only curative option to date is the use of neoadjuvant therapy followed by surgical resection.
Traditional open esophageal resection is associated with a high morbidity and mortality rate. Furthermore, this
approach involves long intensive care unit stay, in-hospital stay and long recovery period. Minimally invasive
esophagectomy could reduce the morbidity and accelerate the post-operative recovery.
Methods/Design: Comparison between traditional open and minimally invasive esophagectomy in a multi-center,
randomized trial. Patients with a resectable intrathoracic esophageal carcinoma, including the gastro-esophageal
junction tumors (Siewert I) are eligible for inclusion. Prior thoracic surgery and cervical esophageal carcinoma are
indications for exclusion. The surgical technique involves a right thoracotomy with lung blockade and laparotomy
either with a cervical or thoracic anastomosis for the traditional group. The minimally invasive procedure involves a
right thoracoscopy in prone position with a single lumen tube and laparoscopy either with a cervical or thoracic
anastomosis. All patients in both groups will undergo identical pre-operative and post-operative protocol. Primary
endpoint of this study are post-operative respiratory complications within the first two post-operative weeks
confirmed by clinical, radiological and sputum culture data. Secondary endpoints are the operative data, the post-
operative data and oncological data such as quality of the specimen and survival. Operative data include duration
of the operation, blood loss and conversion to open procedure. Post-operative data include morbidity (major and
minor), quality of life tests and hospital stay.
Based on current literature and the experience of all participating centers, an incidence of pulmonary
complications for 57% in the traditional arm and 29% in the minimally invasive arm, it is estimated that per arm
48 patients are needed. This is based on a two-sided significance level (alpha) of 0.05 and a power of 0.80.
Knowing that approximately 20% of the patients will be excluded, we will randomize 60 patients per arm.
Discussion: The TIME-trial is a prospective, multi-center, randomized study to define the role of minimally invasive
esophageal resection in patients with resectable intrathoracic and junction esophageal cancer.
Trial registration (Netherlands Trial Register)NTR2452
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Background
The incidence of esophageal cancer is increasing in the
Western world. In the Netherlands, in the year 1990
some 807 patients were diagnosed with esophageal
cancer, whereas in 2005, this number reached a stagger-
ing 1546 [1]. It is expected that this rise in incidence
will continue in the years to come. This substantial
increase in incidence can be accounted for by an
increase in the number of adenocarcinomas diagnosed.
Approximately one third of the patients are consid-
ered candidates for a curative approach. Surgical resec-
tion with radical lymphadenectomy, usually after
neoadjuvant chemotherapy or chemo-radiotherapy,
remains the only curative option for resectable esopha-
geal cancer. Surgery is considered when the tumor is
staged as cT1-3 N0-1 M0. Despite the curative intent,
some 30% of all resections have microscopically residual
disease (R1). Most patients present with stage III eso-
phageal cancer, which has a 5-year survival of approxi-
mately 20-25% [2]. In addition, the possible value of
neoadjuvant chemoradiotherapy or chemotherapy is cur-
rently being investigated. However, a meta-analysis by
Gebski et al. has shown that surgery following chemora-
diotherapy for both squamous cell carcinoma and ade-
nocarcinoma has a survival benefit of 13% after 2 years.
For neoadjuvant chemotherapy this survival benefit was
7% after 2 years for adenocarcinomas [3].
The three main surgical approaches utilized worldwide
for intrathoracic esophageal cancer are the following:
(1) the three stage transthoracic resection (i.e. right pos-
tero-lateral thoracotomy, laparotomy and cervicotomy)
with a cervical anastomosis; (2) the two stage transthor-
acic resection (i.e. laparotomy, and right postero-lateral
thoracotomy, including the Ivor Lewis approach with an
intrathoracic anastomosis); and (3) the two stage trans-
hiatal resection (i.e. laparotomy and cervicotomy with
cervical anastomosis) [4]. Transhiatal esophagectomy
according to Orringer is generally performed for gastro-
esophageal junction cancers [5]. Nevertheless, cancer of
the lower esophagus metastasized, according to the
Tumor-Node-Metastasis classification, in more than
45% to the lymph nodes in mediastinum and carina.
Therefore patients with reasonable general condition are
increasingly surgically approached transthoracically.
In the randomized study by Hulscher et al. and long
term follow-up, comparing the transhiatal and trans-
thoracic esophageal resection, an important trend of
better survival has been observed in the transthoracically
approached patients [6,7]. This transthoracic procedure
is associated with a high morbidity and mortality rate of
approximately 50-70% and 5% respectively [6]. More-
over, the extensive nature of this open approach has a
significant negative impact on the quality of life of these
patients and is associated with a long in-hospital
recovery.
Minimally invasive esophageal (MIE) resection for
cancer avoiding the thoracotomy and laparotomy can
reduce the amount of trauma of the required surgery
with the same oncological value. This will imply a
reduction of the post-operative morbidity, a shortening
of the recovery time and an increase of quality of life.
Evidence of the short term benefits of minimally inva-
sive surgery over open procedures with similar oncolo-
gical outcome is accumulating. Less perioperative
complications, shorter hospital stay and faster post-
operative recovery appear to be the main advantages.
MIE involves a right thoracoscopy and laparoscopy,
either with a cervical or intrathoracic anastomosis. The
thoracic phase of this procedure can be performed
through a lateral right thoracic approach with a right
lung block by selective intubation or in prone position
without selective lung block. This prone approach,
with partial lung collapse, will result in lower percen-
tage of pulmonary complications [8,9].
To date, no randomized trials have been performed
comparing any modality of minimally invasive esophagect-
omy with an open traditional approach [10]. Given the
values of postoperative morbidity, quality of life and qual-
ity of the specimen, the aim of this prospective rando-
mized study is to compare the MIE by right thoracoscopy
in prone position and laparoscopy with the open esopha-
geal resection by right thoracotomy and laparotomy in left
lateral decubitus, for those patients possessing intrathor-
acic resectable esophageal cancer. This comparison will
provide further evidence supporting the minimally invasive
and cost-effective approach for esophageal cancer.
Methods
Study objectives
The TIME trial is prospective, multi-center, randomized
study comparing traditional transthoracic esophageal
resection with minimally invasive resection for esopha-
geal cancer. Patients with resectable intrathoracic eso-
phageal cancer are randomized for either (a) minimally
invasive transthoracic esophageal resection in prone
position or (b) traditional open transthoracic esophageal
resection. Our hypothesis is that patients undergoing a
minimally invasive esophagectomy have fewer morbidity,
a shorter duration of the intensive care unit (ICU)
admission and a better quality of life than following the
traditional approach.
Endpoints
The primary endpoint of this study concerns the
respiratory complications (i.e. infections) within two
weeks after the operation. This is categorized as: grade
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1) initial respiratory distress after operation with conti-
nuation of mechanical ventilation; grade 2) after suc-
cessful detubation, clinical manifestation of respiratory
infection caused by (broncho) pneumonia, confirmed by
thorax X-ray or CT scan of the thorax and a positive
sputum culture; and grade 3) other thoracic infections
like post-operative empyema either caused or not by
leakage from the gastric conduit necessitating drainage
or reoperation [modified from Hulzebos et al., [11]].
Consequences for patients range from extensive phy-
siotherapy, involving oxygen and specific antibiotics to
intubation and mechanical ventilation. Furthermore,
important respiratory deterioration after extubation,
involving reintubation and mechanical ventilation will
lead to the necessity of a CT scan of the thorax and
abdomen, and thus endoscopic examination of the gas-
tric tube and anastomosis in order to rule out a leakage.
The secondary endpoints are operation related events
(e.g. duration of operation, blood-loss and conversion to
open procedure in MIE group) and re-operations. More-
over, general morbidity (major and minor) is recorded.
Minor complications are defined as wound infections,
venous thrombosis or other. Major complications
consist of- apart from respiratory complications- post-
operative bleeding, anastomosis leakage, mediastinitis,
and re-operations within the in-hospital period. Further-
more, post-operative recovery data are length of ICU
and hospital stay (days), type and number of analgesics
needed after operation, VAS-pain-score, return to fluid
and normal diet, quality of life questionnaires (SF-36
and EORTC QLQ-OES18) [12], and quality of the speci-
men resected (length of specimen, number and location
of lymph nodes resected, and circumferential resection
margin). Also hospital mortality and readmissions are
recorded. Furthermore survival will be analyzed.
Power of the study
According to the published literature and own experi-
ence at the VU university medical center a difference in
respiratory infections of 28% is found between the tradi-
tional open procedure (57%) and the MIE procedure
(29%) [6,7,9,13-15]. To demonstrate this difference of
28%, using a alpha = 0.05 and beta = 0.80, two groups
of 48 patients are needed. This is based on a two-sided
significance level (alpha) of 0.05 and a power of 0.80.
Estimating that approximately 20% of the patients may
be excluded, 60 patients will be randomized per arm.
Inclusion criteria
Candidates to be included in this study are all patients
with a histologically proven squamous cell carcinoma,
adenocarcinoma or undifferentiated carcinoma of the
intrathoracic esophagus and Siewert I junction tumors
which are surgically resectable (T1-3, N0-1, M0) and
treated by neoadjuvant therapy. The age of the patients
must be ≥ 18 and ≤ 75 years. Moreover, the included
patients must have a European Clinical Oncology Group
(ECOG) performance status of 0, 1 or 2; and their writ-
ten informed consent is obligatory.
Exclusion criteria
Patients are excluded as subjects if there is a carcinoma
of the cervical esophagus or have undergone prior thor-
acic surgery or no informed consent is provided. An
exclusion list is maintained by all participating centers in
order to analyze the quality of the randomization rate.
Participating surgeons and clinics
To prevent surgeon bias, the open and laparoscopic
operations have to be performed by experienced sur-
geons in conventional esophageal resections with experi-
ence of at least 10 minimally invasive esophagectomies.
Duration of operation, conversion to open surgery, and
complication rate may be related as factors to experi-
ence, yearly volume and the learning curve of the parti-
cipating surgeon [16]. The surgeons in the three Dutch
centers have been proctored by the two experienced
minimally invasive surgeons of the VU university medi-
cal center. After the fist five patients operated on by an
combined team, the video’s of the last two of a series of
15 patients who had undergone a minimally invasive
approach were examined by the VU university medical
center surgeons. Only the surgeons with sufficient
experience and skill after the proctoring series are
allowed in participation in the trial. The surgeons of the
two other centers are already well experienced in mini-
mally invasive esophagectomy. In order to prevent insti-
tution bias, only hospitals with high volume (>20
esophagectomies/year) will participate in this trial.
Six European academic and non-academic centers will
participate in the study: Academic Medical Center,
Amsterdam, the Netherlands; Atrium Medical Center,
Heerlen, the Netherlands; Canisius Wilhelmina Zieken-
huis, Nijmegen, the Netherlands; Hospital Universitari
de Girona, Dr Josep Trueta, Girona, Spain; I.R.C.C.S.
Policlinico San Donato, Milan, Italy; and VU university
medical center (Vumc), Amsterdam, the Netherlands.
Randomization
The patient will be informed about the trial at the outpati-
ent clinic. When informed consent is obtained, the patient
will be randomized at the outpatient clinic. Randomization
is performed per center by an internet randomization
module maintained by coordinators at the VUmc. As
some heterogeneity is expected, e.g. difference in type of
neoadjuvant therapy protocol, randomization will be stra-
tified for each center. A flowchart of the study protocol is
seen in Figure 1.
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Data collection and statistics
Data are transcribed via datasheets on paper and sent to
the VUmc by surface mail. Data are collected daily until
the day of discharge. The quality of life questionnaires
(SF-36 and EORTC-OES18) are completed by the
patient starting preoperatively and post-operatively at
6 weeks, 3 months, 6 months, and at 1 year. There will
be regular contact between the study-coordinators and the
participating centers. One research fellow will monitor the
data of all included patients. Using a SPSS database
Neoadjuvant therapy according 
to local protocol 
Assessment for eligibility 
Exclusions  (n=   ) 
 
Follow-up 
 6 weeks 
 3 months 
 6 months 
 1 year 
Intervention 
Primary endpoint 
Respiratory  
complications  
time-point 2 
weeks 
Allocated to Traditional 
Esophagectomy 
Intervention 
Primary endpoint 
Respiratory 
complications  
time-point 2  
weeks 
Allocated to Minimally 
Invasive Esophagectomy Allocation 
Follow-Up 
Enrollment 
Randomization 
Intervention 
Follow-up 
 6 weeks 
 3 months 
 6 months 
 1 year 
Neoadjuvant therapy according 
to local protocol 
Figure 1 TIME-trial flowchart.
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containing all required parameters, data analysis will be
performed in accordance with the intention-to-treat prin-
ciple, additional per-protocol analysis will also be per-
formed. Groups are, where appropriate, compared using
an Independent Samples T-test, otherwise a Wilcoxon
test, or Chi-square test. Pain scores will be analyzed using
repeated measures analysis.
Ethics
This study is conducted in accordance with the princi-
ples of the Declaration of Helsinki and ‘good clinical
practice’ guidelines. The independent medical ethics
committees of the participating centers have approved
the study protocol. Prior to randomization, written
informed consent will need to be obtained from all
patients.
Surgical Technique
Pre-operative regimen
Pre-operative preparation has the aim of keeping
patients physically and mentally as optimal as possible
during the whole period of pre-operative period. Com-
plete information about the diagnostic phase, randomi-
zation, neoadjuvant therapy and surgical intervention is
very important here. Coordination of this preparation
period is undertaken by a research nurse, the study-
coordinator and the participating surgeons.
All patients will have regular consultations by a dieti-
cian during the whole pre-operative path. Supplemental
nutritional feeding can be initiated and if necessary a
thin nasogastric tube can be placed for feeding purposes.
Also, all patients will be consulted by a physiotherapist
for exercises with emphasis on respiratory improvement.
If necessary, a psychological consultation will be
arranged.
Neoadjuvant therapy
All patients included will pre-operatively receive neoad-
juvant therapy: chemoradiotherapy or chemotherapy
alone according to local protocol. Each center will treat
patients, either in category open operation or MIE, in
the same way.
Esophageal resection
The open operation as well MIOE operation consists of
a two-field esophageal resection with gastric tube forma-
tion followed by cervical or thoracic anastomosis.
For patients undergoing a thoracotomy, a high epi-
dural catheter and a double tube are placed for selective
intubation.
Traditional transthoracic esophagectomy
In the open group a three-stage procedure is followed.
After selective intubation to block the right lung, the
patient is placed in a left lateral decubitus position. The
first stage is started with a right posterolateral thoracot-
omy. The esophagus and its overlying mediastinal pleura
is mobilized with mediastinal and carina lymphadenect-
omy. For the second stage, the patient is turned to a
supine position. Through a supra-umbilical laparotomy
the stomach is mobilized with special care of the gastro-
epiploic vessels and a lymphadenectomy of the celiac
trunk is performed. The dissection finalizes at the hiatus
with anterior extension and careful dissection of the gas-
tro-esophageal junction along the planes. For the last stage
a cervical incision is made and the esophagus dissected
free. Retrieval of the specimen through the laparotomy
wound is performed and a gastric conduit created. No
pyloroplasty is usually performed. A jejunostomy catheter
is placed for feeding purposes. A gastric tube-esophageal
anastomosis is then established in an end-to-side fashion.
If an thoracic anastomosis is made, the first phase of it
commences with an abdominal approach involving the
patient in supine position. The second phase (thoracic)
is performed with the patient in a left decubitus posi-
tion. The retrieval of the specimen will be achieved
through the thoracotomy wound. The anastomosis will
be made high in the thorax, proximal at the level of the
divided vena azygos.
Minimally invasive transthoracic esophagectomy
The MIE also has a three-stage procedure. The differ-
ence from the procedure of the open operation is that
there is no need for selective intubation with the excep-
tion of patients in whom an thoracic anastomosis is
planned (a Fogarty balloon catheter is placed under
bronchoscopy view in the right primary bronchus and
inflated only during the anastomosis phase). After
anesthesia, the patient is turned to a prone position.
Four trocars are placed along the medial edge of the
scapula. Modest insufflation using CO2 will raise the
intrathoracic pressure between 6 and 8 mmHg. Radical
esophagectomy is performed along the pericard sac, pul-
monal veins, right bronchus, aorta resecting the esopha-
gus with the mediastinal pleura and lymphadenectomy
(peri-esophageal, lower posterior mediastinal, carina and
right paratracheal). After completion of this phase the
thorax is drained and the trocar sites are closed.
The patient is then placed in a supine position. After
introduction of four trocars the mobilization of the sto-
mach is performed similar to the traditional procedure
(with paracardiac left and right, lesser and greater curva-
ture and celiac trunc lymphadenectomy). After dissec-
tion of the esophagus at cervical level, the specimen is
retrieved through a well protected trans-umbilical mini-
laparotomy (6-8 cm). The esophageal-proximal stomach
resection is performed extra-corporeally and a small gas-
tric conduit (3-4-cm) created, then conducted to the
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cervical wound and there anastomosed. A jejunostomy
catheter is placed.
If a thoracic anastomosis is made (two phase procedure),
the first phase commences with a laparoscopy involving
the patient in supine position. The only difference with
the three stage MIE (abovementioned) is the laparoscopic
creation of the gastric tube and hiatal dissection. A jeju-
nostomy catheter is placed. The second phase (thoracic) is
performed with the patient in prone decubitus position.
The esophagus is dissected free up to the distal trachea,
the azygos vein is divided and lymphadenectomy per-
formed. After division of the esophagus, a purse string is
placed at the proximal esophagus. A posterior mini-thora-
cotomy (6 cm) is performed, the lung is blocked, and a 25
circular stapler anvil placed in the proximal esophagus.
The specimen is retrieved, resected and through it the cir-
cular stapler is placed and an end-to-side anastomosis per-
formed. The rest of the loop is resected by an endoscopic
stapler and the thoracic cavity drained.
Post-operative management
Patients in both groups will receive similar post-operative
treatment. All patients will after surgery be admitted intu-
bated at the intensive care unit (ICU). After stabilization
and detubation, the patient will if indicated be admitted to
the general surgical ward or to the medium care unit
(MCU). In the first days after surgery analgesics are admi-
nistered by the epidural route. In the event of epidural fail-
ure, post-operative pain will be treated intravenously by a
‘patient controlled analgesia’ (PCA); when necessary
through a pump with morphine. Patients will be instructed
about the PCA pump by an anesthesiologist and morphine
doses will be noted. Patients will have a nasogastric tube
in-situ for at least 5 days as some gastric conduit disten-
sion is expected. All patients will receive postoperative
physiotherapy for breathing-exercises the day after sur-
gery. To regain early mobilization, starting day 1, patients
are encouraged to sit out of bed in the general surgical
ward. Enteral feeding is commenced day 1 after operation
through the jejunostomy and increased to optimal feeding
at day 3. At day 5, after gastrographine swallow X ray, the
nasogastric tube is retired and started with liquids. Normal
diet can be progressively resumed while jejunostomy feed-
ing is decreased. Patients will be discharged when they are
able to eat normal food, can walk and are comfortable
with oral analgesia. Delay to “social” reasons will be noted.
Completion of the feeding over the jejunostomy may be
continued after discharge. Patient follow-ups are carried
out at the outpatient clinic at 6 weeks, 3 months, 6
months and 1 year after discharge. During these visits, the
quality of life questionnaires (SF-36 and EORTC QLQ-
OES18) will be completed. The regular follow-up will con-
tinue up to 5 years after surgery.
Discussion
Surgery on cancer of the esophagus is considered to be
one of the most extensive and traumatic oncological
surgical procedures. Open resection not only involves a
long operation time and large incisions but also necessi-
tates post-operative care in the intensive care unit, a
long in-hospital recovery with decreased quality of life
and carries a significant risk of morbidity and death.
MIE can reduce the post-operative morbidity, in parti-
cular the respiratory complications which are most
encountered. Different landmark studies have reported
significantly low pulmonary complications rates using
the minimally invasive transthoracic approach. Palani-
velu et al. report in their minimally invasive series of
130 patients in prone-position, 2.3% pulmonary compli-
cations [9] whereas Luketich et al. report in their series
of 222 patients in left lateral decubitus MIE, 18% pul-
monary complications [13]. Other authors report a simi-
lar incidence in pulmonary complications with probably
a slight advantage for the thoracoscopic resection in
prone position, being in the experience of the VUmc
around 25%. In contrast, Hulscher et al. observed 57%
pulmonary complications in patients undergoing the tra-
ditional three-stage transthoracic esophagectomy [6].
Furthermore, median length of ICU stay was 1 day in
the series of Palanivelu and Luketich whereas in the tra-
ditional series of Hulscher the ICU stay was 6 days.
Oncologically, the type of resected specimen and lymph
nodes are comparable with the open series and disease-
free and overall survival reported for MIE and tradi-
tional resection are quite comparable. These aforemen-
tioned landmark studies favor minimally invasive
esophagectomy in terms of pulmonary complications
and recovery.
Despite the advantages of the procedure, still only a
small percentage of all esophageal resections for cancer
are performed minimally invasive. Although, important
MIE series have demonstrated feasibility and important
short term advantages, yet to date the beneficiary effects
of minimally invasive esophagectomy have not been pro-
ven by a randomized trial [10]. Therefore, a randomized
comparison between traditional esophagectomy and
minimally invasive esophagectomy is necessary. This
randomized trial can provide further evidence support-
ing the minimally invasive and cost-effective approach
for esophageal cancer.
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